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Bone marrow stromal cells
Tumour microenvironment
Exosomes
Interleukin 8Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized by the Bcr–Abl onco-
protein with constitutive tyrosine kinase activity. Exosomes are nanovesicles released by cancer cells that
are involved in cell-to-cell communication thus potentially affecting cancer progression. It is well known
that bone marrow stromal microenvironment contributes to disease progression through the establish-
ment of a bi-directional crosstalk with cancer cells. Our hypothesis is that exosomes could have a func-
tional role in this crosstalk. Interleukin-8 (IL 8) is a proinﬂammatory chemokine that activates multiple
signalling pathways downstream of two receptors (CXCR1 and CXCR2). We demonstrated that exosomes
released from CML cells stimulate bone marrow stromal cells to produce IL 8 that, in turn, is able to mod-
ulate both in vitro and in vivo the leukemia cell malignant phenotype.
 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Chronic myelogenous leukemia (CML) is a clonal myeloprolifer-
ative disorder characterized by the Philadelphia (Ph) chromosome
encoding the chimeric Bcr–Abl oncoprotein [1]. Bcr–Abl shows a
constitutive tyrosine kinase activity that drives disease progression
by stimulating a number of downstream signalling pathways [2].
Because of its critical role in CML pathogenesis, most therapies
have focused on targeting Bcr–Abl [3]. However, while imatinib
(IM), an ATP-competitive inhibitor of Bcr–Abl kinase, induces
molecular remission in most patients, a number of investigation
have demonstrated the persistence of a leukemic stem cell pool
in the bone marrow (BM) niche even after IM treatment [4]. Fur-
thermore, evidence have accumulated indicating that altered
crosstalk between mesenchymal stromal cells (MSC) and CML cells
may affect leukemia cell survival and resistance to chemotherapy
[5,6]. Nevertheless, little is known about the possible mechanisms
by which the BM microenvironment can modulate the progression
of this disease.Exosomes are nanovesicles released by cancer cells that can
modulate the tumour microenvironment, promoting angiogenesis,
tumour development and metastasis formation [7]. Peinado and
colleagues have recently shown that cancer-derived exosomes
modulate the crosstalk between malignant cells and the bone mar-
row microenvironment through the activation of the MET receptor
tyrosine kinase [8]. Recent data from Kurre’s group examined the
role of exosomes released by acute myeloid leukemia (AML) cells
in modulating cell signalling in the bone marrow microenviron-
ment. They showed that both primary AML blasts and AML cell
lines released exosomes enriched in microRNA relevant to AML
pathogenesis [9]. We have recently showed that LAMA84 CML cells
release exosomes and that the addition of those microvesicles to
vascular endothelial cells (HUVEC) affects in vitro and in vivo angi-
ogenesis though the stimulation of an Interleukin 8-mediated
autocrine loop [10,11]. IL 8 belongs to the family of chemokines re-
lated to C-X-C motif and binds two seven transmembrane domain
receptors, CXCR1 and CXCR-2 [12]. Interestingly, serum IL 8 levels
have been found increased in hematologic malignancies compared
to healthy controls [13] and increased expression of IL 8 and/or its
receptors has been detected in cancer cells and stromal cells sug-
gesting that IL 8 may modulate tumour microenvironment. How-
ever, the exact role of IL 8 in the growth of chronic myelogenous
leukemia cells has not been investigated yet. Here we provide data
showing that LAMA84-derived exosomes are able to activate bonearrow
2 C. Corrado et al. / Cancer Letters xxx (2014) xxx–xxxmarrow stromal cells which in turn release IL 8 acting as an in vitro
and in vivo pro survival factor for chronic myelogenous leukemia
cells.
2. Material and methods
2.1. Ethic statement
All animal experiments were conducted in full compliance with University of
Palermo and Italian Legislation for Animal Care; Dipartimento di Biopatologia e
Biotecnologie Mediche e Forensi (DiBiMef) review board has approved this study.
2.2. Cell culture and reagents
Chronic myelogenous leukemia cell line, LAMA84, was obtained by DSMZ
(Braunschweig, Germany) and cultured in RPMI 1640 medium (Euroclone, UK).
Bone marrow-derived stromal cell line, HS5, was obtained by ATCC (Manassas,
VA, USA) and cultured in DMEM high glucose (Euroclone, UK). Both media were
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin
and 100 lg/ml streptomycin (Euroclone, UK). Recombinant IL 8 (R&D Systems, MN,
USA) was prepared at 10 ng/ll stock solution in sterile phosphate-buffered saline
(PBS), aliquoted and stored at 80 C. SB225002 (Cayman Chemical, Michigan,
USA) was solubilized at 10 mM stock solution in DMSO and stored at 20 C. Work-
ing dilutions were prepared in medium. All other reagents were purchased from
Sigma–Aldrich (St. Louis, MO, USA), if not cited otherwise.
2.3. Exosome preparation
Exosomes released by LAMA84 CML cells after a 24-h culture period in presence
of FBS previously ultracentrifuged (vesicle free media), were isolated from condi-
tioned culture medium by differential centrifugation as described previously
[10,11]. Exosome pellet was washed and then resuspended in PBS. Exosome protein
content was determined by the Bradford assay (Pierce, Rockford, IL, USA).
2.4. Adhesion assay
Adhesion assays were performed as previously described [10]. Brieﬂy, HS5
monolayer was pretreated in a 24-well plate, for 48 or 72 h with 50 lg/ml of
LAMA84-derived exosomes or with exosome-deprived medium as negative control.
After treatment, stromal monolayer was washed with PBS and 0.5  106 cells/well
CML cells were left to adhere for 3.5 h at 37 C. In different set of experiments,
LAMA84 cells were stimulated with recombinant IL 8 (r-IL 8); in presence or not
of different concentrations of SB225002 as indicated and in presence or not of con-
ditioned medium of HS5 previously treated with LAMA84 exosomes. Adhered cells
were stained with haematoxylin eosin, each test group was assayed in triplicate; 15
high power (400) ﬁelds were counted for each condition.
2.5. Migration assay
Migration assays were performed in transwell chemotaxis chambers with 3 lm
pore ﬁlters (NeuroProbe, Cabin John, MD, USA) [11]. Speciﬁcally, LAMA84
(0.5  106cells/ well) were resuspended in 500 ll of RPMI 1% FBS with or without
SB225002 (600–1000–1200 nM), and exposed, as chemoattractant, to conditioned
medium of HS5 previously treated with LAMA84-derived exosomes (50 lg/ml)
for 6, 24, 48 or 72 h, as indicated. After 18 h at 37 C, ﬁlters were removed, ﬁxed
in methanol and stained with Diff-Quick (Medion Diagnostics GmbH, Dudingen,
Switzerland). Each test group was tested in three independent experiments; the
number of migrating cells in ﬁve high-power ﬁelds per well were counted at
400 magniﬁcation.
2.6. RNA extraction and real time PCR
HS5 were grown in 12-well plates and treated with 50 lg/ml of LAMA84-
exosomes for 6, 24, 48 or 72 h. RNA was extracted using the commercially available
illustra RNAspin Mini Isolation Kit (GE Healthcare, Little Chalfont, Buckinghamshire,
UK), according to manufacturer’s instructions. Total RNA was reverse-transcribed to
cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystem,
Foster City, CA, USA). RT-QPCR was performed in 48-well plates using the Step-One
Real-Time PCR system (Applied Biosystem, Foster City, CA, USA). Taqman gene
expression assays for GAPDH (Hs99999905_m1) control and for IL 8
(Hs00174103_m1) were obtained from Applied Biosystems (Foster City, CA, USA).
Real time PCR was performed in duplicates for each data point.
2.7. RT PCR
Conventional PCR was performed using cDNA from LAMA84 cells, obtained as
described above. Primer sequences for CXCR1 were 50TCCTGGGAAATGACACAGCA03
and 50AAGCCAAAGGTGTGAGGCAG03 and for CXCR2 were 50GGGCAACAATACAGCAPlease cite this article in press as: C. Corrado et al., Exosome-mediated crossta
stromal cells triggers an Interleukin 8-dependent survival of leukemia cells, CaAACT03 and 50GCACTTAGGCAGGAGGTCTT03. The reaction conditions were 35 cycles
of 95 C 5 min, 94 C for 30 s, 58 C for 30 s, 72 C for 30 s and a ﬁnal extension
phase at 72 C for 5 min. The PCR products were separated on a 3% agarose gel
and stained with 5 ll ethidium bromide prior to examination under UV light.2.8. ELISA
HS5 conditioned medium was collected from cells treated with 50 lg/ml of
LAMA84-derived exosomes for 6, 24, 48 or 72 h. Conditioned medium aliquots were
centrifuged to remove cellular debris and then IL 8 protein concentrations were
quantiﬁed using the ELISA kit (R&D Systems, MN, USA), according to manufacturer’s
protocol.2.9. Western blot
LAMA84 cells were treated or not for 2, 10 or 30 min with 10 ng/ml of r-IL 8 in
presence or not of 1000 nM SB225002. Total protein cell lysate were obtained and
analyzed by SDS–PAGE followed by Western blot as previously described [11]. Anti-
bodies used in the experiments were: Akt, phospho Akt, ErK 1/2, phospho Erk 1/2,
b-actin (all from Cell Signalling Technology, MA, USA); CXCR1/2 (Santa Cruz Bio-
technology, CA, USA).2.10. Colony formation assay
LAMA84 cells were plated in 6-well (2000 cell/ml/well) in Iscove’s-methylcellu-
lose medium (Methocult H4230, Stem Cell Technologies, Vancouver, Canada) con-
taining or not r-IL 8 (2, 5, 10 ng/ml); in presence or not of SB225002 300–600 nM
and in presence or not of conditioned medium of HS5 previously treated with
LAMA84 exosomes. After 14 days of culture, LAMA84 colonies were observed by
phase-contrast microscopy and photographed. The area of twenty LAMA84 colonies
per condition were measured with the IMAGE-J software (http://rsbweb.nih.gov/ij/).2.11. CML mouse xenograft
Male NOD/SCID mice four-to-ﬁve week old were purchased from Charles River
(Charles River Laboratories International, Inc., MA, USA) and acclimated for a week
prior to experimentation. Mice received ﬁltered water and sterilized diet ad libitum.
Animals were observed daily and clinical signs were noted. Mice were randomly as-
signed to four groups of seven. Each mouse was inoculated subcutaneously (sc) in
the right ﬂank with viable single cells (2  107) suspended in 0.2 ml of PBS with:
(i) r-IL 8 (200 ng/mouse), (ii) SB225002 (1000 nM), (iii) PBS (vehicle) or (iv) r-IL 8
plus SB225002. The day of injection was considered as day 0. Treatments were re-
peated twice a week, in the tumour site. Tumour xenografts were measured and
mice were weighed twice a week. Tumour volume was determined by calliper by
using the following formula: L W2/2 = mm3 where L and W are the longest and
shortest perpendicular measurements in millimeters, respectively. The same for-
mula was used to calculate tumour weights assuming that 1 mm3 = 1 mg. Animals
were euthanized at day 50, tumour was prelevated and tumour weight was
measured.2.12. Statistics
Data were expressed as means ± SEMs of three independent experiments.
Statistical analysis was performed by using a paired samples t test. Differences were
considered to be signiﬁcant when p values were smaller than 0.05.3. Results
3.1. LAMA84-derived exosomes induce the expression of IL 8 in HS5
Recent data from our laboratory suggest that CML exosomes can
modulate angiogenesis through the stimulation of an IL 8-mediated
autocrine loop in endothelial cells. In order to evaluate if exosomes
released from CML cells may affect the production of IL 8 in other
cells composing the bone marrow microenvironment, we treated
HS5 BM stromal cells with 50 lg/ml of exosomes and measured
IL 8 expression. Fig. 1 shows that LAMA84 exosomes contain a little
amount of IL 8, as previously demonstrated [10], but the treatment
of HS5 with LAMA84-exosomes increases the expression of IL
8 mRNA (Fig. 1a) and its release in the HS5 conditioned medium
(Fig. 1b) thus suggesting that IL 8 expression in bone marrow
microenvironment is modulated by leukemia exosomes.lk between chronic myelogenous leukemia cells and human bone marrow
ncer Lett. (2014), http://dx.doi.org/10.1016/j.canlet.2014.03.009
Fig. 1. (a) Treatment of HS5 monolayer with LAMA84 exosomes up to 72 h increases the mRNA expression of IL 8 (p < 0.05). (b) ELISA assay shows that treatment of HS5
monolayer with LAMA84 exosomes up to 72 h induces the release of IL 8 in the conditioned medium (c.m.); IL 8 concentration was also evaluated in the LAMA84 exosomes
(p < 0.05). (c) CXCR1 and CXCR2 mRNA expression in LAMA84 has been validated through rt-PCR (left panel); CXCR1 and CXCR2 protein expression in LAMA84 cells (lane 1)
and LAMA84 cells treated with 10 ng/ml of rIL 8 for 300 (lane 2) has been validated through Western blot analysis. Blot was then stripped and subsequently reprobed with
antibody against b-actin to ensure equal loading.
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Interleukin 8 is a well known promigratory and proangiogenic
stimulus in many cancers but it has been also demonstrated to reg-
ulate other malignant phenotypes in solid tumours; little is known
on its possible role in CML. We ﬁrst examined the expression of IL 8
receptors in LAMA84 cells. As shown in Fig. 1c, RT-PCR and
Western blot analyses conﬁrmed that both CXCR1 and CXCR2 are
present in CML cells. Moreover the treatment of LAMA84 cells with
recombinant IL 8 (rIL 8) slightly increases protein expression.
Adhesion of leukemia cells to BM stroma is known to enhance cell
survival. As shown in Fig. 2a upper panel, treatment of CML cells
with 5 or 10 ng/ml of rIL 8 for 48 h resulted in an increased and
dose dependent adhesion to HS5. Co-treatment of LAMA84 with
rIL 8 and CXCR1–2 inhibitor, SB225002 (SB), reverted the effects
(Fig. 2a). Moreover the presence of conditioned medium of HS5
pretreated with LAMA84 exosomes increases the LAMA84 adhe-
sion on stromal monolayer and SB reduces these effects (Fig. 2b).
In Fig. 2a lower panel is shown a phase contrast micrograph of
the adhesion of CML cells adhering to HS5 monolayer. A reproduc-
ible dose-dependent inhibition of LAMA84-motility towards
exosome-stimulated HS5 conditioned medium was also found
after SB treatment (Fig. 2c). These data suggest that IL 8 released
in the conditioned medium of HS5 pre-treated with CML-exosomes
is able to modulate LAMA84 malignant behaviour.Fig. 2. (a) Upper panel: pre-treatment of LAMA84 with 5 or 10 ng/ml of IL 8 for 48 h
increases CML cell adhesion to stromal cells. The addition of IL 8 receptors inhibitor
(SB 225002) reverts these effects (p < 0.01; p < 0.001). Lower panel: a represen-
tative phase contrast micrograph showing the adhesion of rIL 8-treated-LAMA84
cells to HS5 monolayer. (b) The presence of conditioned medium of HS5 pretreated
with LAMA84 exosomes increases the LAMA84 adhesion on stromal monolayer and
cotreatment with SB reduces these effects (Fig. b). (c) Cotreatment of cells with IL 8
and SB decreases, in a dose dependent manner, LAMA84 migration towards
conditioned medium of HS5 treated or not for different times (6–24–48–72 h) with
LAMA84-exosomes (exo) (p < 0.01).3.3. LAMA84-derived exosomes promote cell adhesion on HS5 stromal
cells
To evaluate the potential towhich extent CML exosomes are able
to modify the surrounding microenvironment, we examined the
adhesion of LAMA 84 cells to HS5 monolayer following treatment
of stromal cells with the nanovesicles. Fig. 3 shows that treatment
of bone marrow cell monolayer with 50 lg/ml of LAMA84-derived
exosomes for 48–72 h caused a statistically signiﬁcant increase of
LAMA84 adhesion to HS5 cells. Furthermore, a reproducible dose-
dependent inhibition of LAMA84 adhesion on exosome-stimulated
HS5 monolayer was found after SB treatment, thus suggesting thatPlease cite this article in press as: C. Corrado et al., Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow
stromal cells triggers an Interleukin 8-dependent survival of leukemia cells, Cancer Lett. (2014), http://dx.doi.org/10.1016/j.canlet.2014.03.009
Fig. 3. Treatment of HS5 monolayer with LAMA84 exosomes for 48–72 h increases
CML cell adhesion to stromal cells, addition of SB reduces these effects (p < 0.01;
p < 0.001). Lower panel: a representative phase contrast micrograph showing the
adhesion of LAMA84 cells to exosome-treated HS5 monolayer.
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marrow and IL 8 is involved in this process.3.4. IL 8 promotes CML cells survival in vitro
IL 8 signallingpromotes angiogenic responses in endothelial cells
but also increases proliferation and survival of cancer cells [12]. We
therefore evaluated the role of IL 8 in the survival of leukemic cells.
Colony formation assay shows that LAMA84, treatedwith escalating
doses of r IL 8 (2, 5, 10 ng/ml), are able to form colonies inmethylcel-
lulose with a greater area than control cells (Fig. 4a). The addition ofFig. 4. (a) The addition of 2, 5 or 10 ng/ml of rIL 8 increases the area of LAMA84 colonies in
600 nM of SB reverts these effects (p < 0.01). (c) The presence of conditioned medium o
methylcellulose with respect to control and SB reverts these effects (p < 0.01). (d) Wester
triggers phosphorylation of Akt but not of ERK without altering the total level of these pro
stripped and subsequently reprobed with antibody against b-actin to ensure equal loadi
levels ± SD.
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lated colonies areas without affecting the area of control colonies
(Fig. 4b). Methocult assay was also performed with LAMA84 cells
in presence of exosome-stimulated HS5 conditioned medium, con-
ﬁrming the data previously shown (Fig. 4c). To better understand
the role of IL 8 in survival of LAMA84 cells, we then investigated
the signal transduction pathways activated in LAMA84 cells after
IL 8 treatment. Western blot analysis show that there was a time-
dependent increase of Akt phosphorylation, reaching a 15-fold
increase, after 30 min of r IL 8 treatment (10 ng/ml) (Fig. 4d). IL 8
treatment had no effects on ERK½ phosphorylation suggesting that
this chemokine does not affect CML proliferation, as also demon-
strated by proliferation assays (data not shown). These results
strongly suggest a role of IL 8 in promoting the survival of leukemic
cells.
3.5. IL 8 promotes tumour growth of leukemia cells in vivo
On the basis of the in vitro effects of IL 8 on LAMA84 malignant
behaviour, we next examined the in vivo role of this cytokine using
a xenograft CML tumour model. For this purpose, LAMA84 cells
were inoculated subcutaneously on NOD/SCID mice and subse-
quently treated locally twice a week with IL 8, vehicle (PBS), SB
or IL 8 plus SB. After ﬁfty days mice were sacriﬁced and tumours
were removed to calculate tumours weight. The histogram in
Fig. 5a represents the mean of tumour weight for each group. Mice
treated with IL 8 develop larger tumours than control groups (PBS
or SB); co-treatment with SB results in a slower tumour growth
compared with mice treated with IL 8 alone.
4. Discussion
In this work we provide evidence that exosome-mediated cross-
talk between human chronic myelogenous leukemia cells and bonemethylcellulose with respect to control (p < 0.05; p < 0.01). (b) Addition of 300 or
f HS5 pretreated with LAMA84 exosomes increases the area of LAMA84 colonies in
n blot analysis shows that 2, 10, 30 min treatment of CML cells with 10 ng/ml of IL 8
teins; treatment of LAMA84 with 1000 nM SB reduces these effects. Blots were then
ng. Numbers under the ﬁgure represent values from densitometric analysis of P Akt
lk between chronic myelogenous leukemia cells and human bone marrow
ncer Lett. (2014), http://dx.doi.org/10.1016/j.canlet.2014.03.009
Fig. 5. LAMA84 cells (2  107) resuspended in PBS were inoculated subcutaneously in NOD/SCID mice. Mice were randomly assigned to 4 groups of 7 mice and were treated
with IL 8 (200 ng/mouse), PBS (vehicle), SB (1000 nM) or IL 8 (200 ng/mouse) plus SB (1000 nM). All treatments were administrated in the tumour site, twice a week. Tumour
xenografts were measured twice a week and tumour weight was calculated. All mice were euthanized 50 days after cells injection. Histogram represents the mean of tumour
weight for each group ± SD (p < 0.05; p < 0.01).
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mia cells through the activation of an IL 8-dependent signalling. Our
previous ﬁndings demonstrated that CML cell lines such as LAMA84
and Imatinib-resistant LAMA84 cells as well as patients leukemic
blasts, release exosomes that directly affect endothelial cells thus
modulating the process of neovascularization. Speciﬁcally, the stim-
ulation of HUVEC with CML exosomes activates signal transduction
pathways leading to the release of IL 8 and the induction, in vitro and
in vivo, of an angiogenic phenotype [10,11]. Another important com-
ponent of bone marrow, in addition to the endothelial cells, is rep-
resented by stromal cells; these cells secrete a wide range of
cytokines, growth factors andmatrix proteins involved in the hema-
topoiesis [14]. In several hematological malignancies, it has been
demonstrated that MSC promote a pro-tumorigenic environment.
In multiple myeloma, the integrin-mediated interaction of cancer
cells with MSC, upregulates the secretion of soluble factors such
as IGF-1, FGF, IL-6 and others that provide growth advantage and
drug resistance to multiple myeloma cells [15]. Activation of a sig-
nalling cascade downstream integrin engagement has been also
demonstrated to play a role in survival and chemoresistance of bone
marrow-resident acute myelogenous leukemia cells [16]. Our stud-
ies add another piece of information in the complex interaction be-
tween bone marrow microenvironment and cancer cells by
introducing the role of cancer secreted exosomes. We demonstrate
that treatment of bonemarrow stromal cellswith CML-derived exo-
somes increasedmRNAandprotein expression of Interleukin-8. IL 8,
a potent proangiogenic factor belongs to the family of chemokines
related by a C-X-Cmotif and binds to two seven transmembrane do-
main receptors, CXCR-1 and CXCR-2 [12], both present on CML cells
(Fig. 1). These two receptors are also functional since we observed
that treatment of LAMA84 cells with recombinant IL 8 activates
intracellular signalling leading to increased adhesion, motility andFig. 6. Working hypothesis on CML-bone marrow crosstalk. Chronic myelogenous leukem
turn, modulates angiogenesis and leukemia cell survival.
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ciﬁc inhibitor of these two receptors,was able to revert the observed
phenotypes. Interestingly, IL8 seems to increase receptor expres-
sion thus potentially amplifying the cell response to the cytokine
(Fig. 2). A number of investigation has demonstrated that IL 8 plas-
ma concentrations are signiﬁcantly increased in patients with CML
[17,18] and these observations have been mainly related to the in-
creased vascularity of patient’s bone marrow but never, to our
knowledge, with modulation of leukemia cells properties. Using
adhesion and migration assays, we found that IL 8 or LAMA84 con-
ditioned medium increased CML cells motility as well as the ability
to adhere to a monolayer of bone marrow stromal cells. An in-
creased interaction was also observed when HS5 were stimulated
by exosomes released from LAMA84 cells (Fig. 3). The concept of
MSC interactions is of particular importance in CML. A number of
recent studies have shown that human MSC preserve the prolifera-
tive ability and therapy resistance of leukemia cells. Jin et al. have
demonstrated that IM-induced CXCR4 expression resulted in an
enhanced migration of CML cells to MSC cells associated with the
inhibition of proliferation and augmented survival of CML cells
[19]. CML stem cells cultured on MSC showed an increased expres-
sion of N-cadherin and an overactivated Wnt-mediated b-catenin
signalling that was determinant for the protection of CML progeni-
tors from drug treatment [20]. It is well known that overexpression
of IL 8 promotes cell proliferation and survival in solid tumours such
as melanoma, prostate, and breast cancer [21–23] while few data
have been produced concerning haematological cancers. Low doses
of IL 8 have been shown to stimulate CD34+ proliferation and
increase cell survival [24]. Colony formation in methylcellulose is
generally considered a reliable system for the in vitro study of tu-
mour growth. In our CML system, treatment of LAMA84 cells with
recombinant IL 8 did not stimulate cell proliferation but enhancedia cells release exosomes that stimulate in stromal cells the secretion of IL 8 that, in
lk between chronic myelogenous leukemia cells and human bone marrow
ncer Lett. (2014), http://dx.doi.org/10.1016/j.canlet.2014.03.009
6 C. Corrado et al. / Cancer Letters xxx (2014) xxx–xxxcell survival as showed by the augmented size of colonies in semi-
solid medium compared to control (Fig. 4). Furthermore, Western
blotting analysis also revealed that the phosphorylation levels of
p-AKT, one of the principal mediators of cell survival, and chemo-
taxis in leukemia cells [25], are increased following the stimulation
of CML cells with r IL 8. Blocking of IL 8 receptors using SB225002
was able to abrogate the IL 8-driven LAMA84 cell survival and phos-
phorylation of AKT in vitro as well as the growth of CML xenograft
in vivo thus indicating a key role of CXCL8/CXCR1–2/AKT signalling
for the growth of CML cells. Similar results, obtained by Hinohara
et al. and by Ming-Chu et al., demonstrated the involvement of
CXCL8 and activation of AKT-dependent signalling pathways in
breast cancer and nasopharyngeal tumour growth respectively
[26,27].
Based on the present and past ﬁndings we propose a model of
exosome-driven CML-stroma interaction which facilitates leuke-
mic cell survival (Fig. 6). It is conceivable to hypothesize that IL 8
secreted by both bone marrow and surrounding cells under the
stimulation of CML exosomes may modulate both myeloid malig-
nant cells and bone marrow cellular compartment thus generating
a paracrine machinery between hematopoietic malignant cells and
microenvironment. In this context, the inhibition of either exo-
somes shedding or modulation of their function may be proposed
as worthwhile approaches to cancer therapy.Conﬂict of Interest
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